National clinical guidelines for the treatment of HCV in adults
- Type
- Guidance
- Published
- 05 June 2018
- Conditions and diseases
- Health protection
Description
The purpose of this guideline is to provide guidance to health board area drug and therapeutics committees on the recommended place in treatment of available hepatitis C (HCV) medicines taking into consideration
- Scottish Medicines Consortium (SMC) guidance
- clinical effectiveness
- price
Files
Media enquiries
If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.
Requesting other formats and reporting issues
If you require publications or documents in other formats, please email phs.otherformats@phs.scot.
To report any issues with a publication, please email phs.generalpublications@phs.scot.
Accessibility disclaimer
The original publisher of this publication became part of Public Health Scotland when it was created on 1 April 2020. This publication may not be fully accessible or meet our current publication standards.
See our accessibility statement for more information.